Compare ALLR & OMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLR | OMH |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 24.4M |
| IPO Year | 2021 | 2022 |
| Metric | ALLR | OMH |
|---|---|---|
| Price | $1.43 | $0.65 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 219.2K | 91.2K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $320,000.00 | N/A |
| Revenue This Year | N/A | $28.40 |
| Revenue Next Year | N/A | $23.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.51 |
| 52 Week High | $2.35 | $1.91 |
| Indicator | ALLR | OMH |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 38.49 |
| Support Level | $1.34 | N/A |
| Resistance Level | $1.80 | $1.09 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 2.50 | 26.75 |
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.